Nutriband Inc
NTRB7.230USD
-0.160-2.17%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
80.07MCap. mercado
PérdidaP/E TTM
Más Datos de Nutriband Inc Compañía
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Información de la empresa
Símbolo de cotizaciónNTRB
Nombre de la empresaNutriband Inc
Fecha de salida a bolsaJun 20, 2017
Director ejecutivoMr. Gareth Sheridan
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 20
Dirección121 S Orange Ave Ste 1500
CiudadORLANDO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal32801-3241
Teléfono14073776695
Sitio Webhttps://nutriband.com/
Símbolo de cotizaciónNTRB
Fecha de salida a bolsaJun 20, 2017
Director ejecutivoMr. Gareth Sheridan
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
667.43K
100.00%
Non-United States
0.00
0.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
Estadísticas de accionistas
Actualizado: dom., 20 de jul
Actualizado: dom., 20 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
Accionistas
Accionistas
Proporción
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
60.16%
Corporation
16.21%
Investment Advisor
2.09%
Investment Advisor/Hedge Fund
0.83%
Research Firm
0.12%
Other
20.59%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
44
8.86M
79.41%
+467.78K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
2023Q2
28
2.95M
37.71%
-29.57K
2023Q1
28
2.96M
37.92%
-64.00
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Botgros (Vitalie)
3.09M
27.68%
+716.50K
+30.22%
Apr 25, 2025
TII Jet Services, LDA
1.81M
16.21%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
15.79%
-103.00
-0.01%
Apr 25, 2025
Glinka (Serguei)
825.00K
7.4%
--
--
Apr 25, 2025
Melnik (Serguei)
820.42K
7.36%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
199.03K
1.78%
+74.44K
+59.75%
Mar 31, 2025
Goodman (Gerald)
86.33K
0.77%
--
--
Apr 25, 2025
Geode Capital Management, L.L.C.
63.55K
0.57%
+1.11K
+1.79%
Mar 31, 2025
Smith (Allan)
41.91K
0.38%
-6.99K
-14.29%
Apr 25, 2025
Patrick (Jeff)
36.61K
0.33%
--
--
Apr 25, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jul 29, 2022
Split
6>7
Fecha
Tipo
Relación
Jul 29, 2022
Split
6>7
